Targeting chemotherapy with 70-gene MammaPrint signature in patients 60 years or younger with node-negative breast cancer is likely to be cost-effective.
Er Chen, MPP
Advertisement
Articles by Er Chen, MPP
Advertisement
Latest Updated Articles
- Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast Cancer
Published: December 21st 2010 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First-in-Class Optune Pax Device for Pancreatic Cancer
2
Bipartisan Break Up Big Medicine Act Targets Vertical Integration in Health Care
3
Contributor: American Patients vs Foreign Governments—A Tale of 2 Value Sets
4
3-Year EPCORE NHL-1 Data Published Showing 53% Have Deep, Durable Remission
5